Identifier | Gender | Age range (years) | Country | Prior participatory experience | |
COS development | Delphi survey | ||||
P1COS1 | Male | 65–74 | UK | No | No |
P2COS1 | Female | ≥75 | UK | No | No |
P3COS2 | Female | 35–44 | UK | No | No |
P4COS3 | Female | Undisclosed | Canada | Yes | Yes |
P5COS2 | Male | 45–54 | UK | No | No |
P6COS3 | Female | 55–64 | Canada | Yes | Yes |
P7COS4 | Female | 55–64 | UK | No | No |
P8COS4 | Female | 55–64 | Netherlands | No | No |
P9COS5 | Female | 35–44 | Ireland | No | No |
P10COS6 | Female | 45–54 | Ireland | Yes* | Yes |
P11COS7 | Male | 55–64 | UK | No | No |
P12COS7 | Female | 65–74 | UK | No | No |
P13COS2 | Female | 55–64 | UK | No | No |
HP1COS1 | Female | 45–54 | Canada | No | Yes |
HP3COS4 | Male | 45–54 | Spain | Yes | Yes |
HP4COS2 | Female | 35–44 | Singapore | Yes | Yes |
HP5COS4 | Male | 35–44 | UK | Yes | Yes |
HP6COS5 | Female | 55–64 | UK | No† | No |
HP7COS5 | Female | 25–34 | Ireland | No‡ | No |
HP8COS5 | Female | 35–44 | UK | No† | No |
HP9COS5 | Female | 65–74 | Ireland | Yes | Yes |
HP10COS6 | Female | 35–44 | Italy | No | No |
HP11COS6 | Male | 65–74 | UK | Yes | Yes |
HP12COS6 | Female | 55–64 | Australia | Yes | Yes |
*Interviewee was also the patient research partner of the core outcome set (COS) study they were interviewed in relation to.
†Two health professionals stated awareness/knowledge of COS and Delphi survey but had not participated previously.
‡One health professional was involved in an earlier phase of the COS study for which they participated in the Delphi survey.